2023: First RSV Vaccine Approved

On This Day in Health: May 3, 2023

On May 3, 2023, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus vaccine licensed in the United States. The authorization covered prevention of lower respiratory tract disease caused by RSV in adults aged sixty and older. Approval was granted to GlaxoSmithKline Biologicals after review of clinical trial evidence. RSV had long been recognized as a threat to infants, but the new vaccine addressed another vulnerable population: older adults, particularly those with heart or lung disease or weakened immune systems. The decision made prevention possible through a new tool, while leaving questions about implementation and continued monitoring to the next stages.

RSV spreads readily and can infect people at any age. Although an infection may resemble an ordinary cold, it can also reach the lower respiratory tract and cause serious illness. In older adults, pneumonia and other complications can lead to hospital treatment. Recognizing that burden changes the meaning of the milestone: this was not simply a vaccine against an unfamiliar abbreviation, but an attempt to prevent a recurring source of illness in an aging population. The initial approval concerned lower respiratory tract disease, rather than a promise to prevent every infection. That distinction helps explain both the clinical trial's purpose and the limits of the authorization.

The main randomized trial compared a single vaccine dose with placebo in adults sixty and older in the United States and other countries. The first season's results supported a substantial reduction in RSV-associated lower respiratory tract disease. Researchers also planned continued follow-up across additional seasons to examine how protection persisted and what repeat vaccination might mean. Common reported reactions included injection-site pain, fatigue and muscle discomfort. Signals involving uncommon neurological conditions warranted additional study, and the FDA required postmarketing investigation of certain serious risks. Approval therefore combined evidence of benefit with obligations to improve the understanding of safety after broader use.

Clinical authorization was only one step in introducing the vaccine. Public health recommendations, availability before the following RSV season and decisions about which adults would benefit most were separate matters. The Indian Health Service's contemporaneous update explicitly distinguished the May 3 approval from later formulary and advisory committee considerations. This sequence is useful when looking back: the announcement opened a preventive option, while health systems still had to determine how to offer it responsibly. May 3 stands as a turning point in adult respiratory disease prevention because it brought RSV into the vaccination landscape. It also illustrates the continuing work behind a medical first, from measuring durability and rare risks to translating a trial result into care for the people most likely to need protection.